Pruritus-Pipeline Review, H1 2015

Pruritus-Pipeline Review, H1 2015

  • Products Id :- GMDHC6350IDB
  • |
  • Pages: 91
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pruritus-Pipeline Review, H1 2015


Global Markets Direct's, 'Pruritus-Pipeline Review, H1 2015', provides an overview of the Pruritus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Pruritus

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pruritus and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pruritus pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pruritus

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pruritus Overview 8

Therapeutics Development 9

Pipeline Products for Pruritus-Overview 9

Pipeline Products for Pruritus-Comparative Analysis 10

Pruritus-Therapeutics under Development by Companies 11

Pruritus-Therapeutics under Investigation by Universities/Institutes 13

Pruritus-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Pruritus-Products under Development by Companies 17

Pruritus-Products under Investigation by Universities/Institutes 19

Pruritus-Companies Involved in Therapeutics Development 20

AlbireoPharma 20

Amorepacific Corporation 21

Cara Therapeutics, Inc. 22

Conrig Pharma ApS 23

Creabilis SA 24

ELORAC, Inc. 25

FAES Farma SA 26

GlaxoSmithKline plc 27

Helsinn Holding S.A. 28

Hydra Biosciences, Inc. 29

LEO Pharma A/S 30

Merck & Co., Inc. 31

NeRRe Therapeutics Ltd 32

Nippon Shinyaku Co., Ltd. 33

RDD Pharma Ltd. 34

Shionogi & Co., Ltd. 35

Tioga Pharmaceuticals, Inc. 36

Trevi Therapeutics, Inc. 37

Vanda Pharmaceuticals Inc. 38

Pruritus-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

A-4250-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

aprepitant-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

asimadoline-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ASN-008-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

bilastine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

C-746-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CR-845-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CRG-010-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

CT-327-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

desloratadine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

GSK-2330672-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

nalbuphine hydrochloride ER-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

naloxone hydrochloride-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

netupitant-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

NS-141-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

orvepitant maleate-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PAC-14028-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

PP-120-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

serlopitant-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecule for Pruritus Ani-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecule to Agonize CB2 for Pruritus-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Small Molecules to Block NaV1.7 Channel for Pain and Pruritus-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

tradipitant-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Pruritus-Recent Pipeline Updates 79

Pruritus-Dormant Projects 88

Pruritus-Discontinued Products 89

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Pruritus, H1 2015 9

Number of Products under Development for Pruritus-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Pruritus-Pipeline by AlbireoPharma, H1 2015 20

Pruritus-Pipeline by Amorepacific Corporation, H1 2015 21

Pruritus-Pipeline by Cara Therapeutics, Inc., H1 2015 22

Pruritus-Pipeline by Conrig Pharma ApS, H1 2015 23

Pruritus-Pipeline by Creabilis SA, H1 2015 24

Pruritus-Pipeline by ELORAC, Inc., H1 2015 25

Pruritus-Pipeline by FAES Farma SA, H1 2015 26

Pruritus-Pipeline by GlaxoSmithKline plc, H1 2015 27

Pruritus-Pipeline by Helsinn Holding S.A., H1 2015 28

Pruritus-Pipeline by Hydra Biosciences, Inc., H1 2015 29

Pruritus-Pipeline by LEO Pharma A/S, H1 2015 30

Pruritus-Pipeline by Merck & Co., Inc., H1 2015 31

Pruritus-Pipeline by NeRRe Therapeutics Ltd, H1 2015 32

Pruritus-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 33

Pruritus-Pipeline by RDD Pharma Ltd., H1 2015 34

Pruritus-Pipeline by Shionogi & Co., Ltd., H1 2015 35

Pruritus-Pipeline by Tioga Pharmaceuticals, Inc., H1 2015 36

Pruritus-Pipeline by Trevi Therapeutics, Inc., H1 2015 37

Pruritus-Pipeline by Vanda Pharmaceuticals Inc., H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 43

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

Pruritus Therapeutics-Recent Pipeline Updates, H1 2015 79

Pruritus-Dormant Projects, H1 2015 88

Pruritus-Discontinued Products, H1 2015 89

List of Figures

Number of Products under Development for Pruritus, H1 2015 9

Number of Products under Development for Pruritus-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Top 10 Routes of Administration, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]


Amorepacific Corporation

Cara Therapeutics, Inc.

Conrig Pharma ApS

Creabilis SA



GlaxoSmithKline plc

Helsinn Holding S.A.

Hydra Biosciences, Inc.

LEO Pharma A/S

Merck & Co., Inc.

NeRRe Therapeutics Ltd

Nippon Shinyaku Co., Ltd.

RDD Pharma Ltd.

Shionogi & Co., Ltd.

Tioga Pharmaceuticals, Inc.

Trevi Therapeutics, Inc.

Vanda Pharmaceuticals Inc.

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]